car -工程先天免疫细胞用于癌症免疫治疗的前景。

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2025-07-18 DOI:10.1038/s43018-025-01015-z

Ourania Tsahouridis, Max Xu, Feifei Song, Barbara Savoldo, Gianpietro Dotti

{"title":"car -工程先天免疫细胞用于癌症免疫治疗的前景。","authors":"Ourania Tsahouridis, Max Xu, Feifei Song, Barbara Savoldo, Gianpietro Dotti","doi":"10.1038/s43018-025-01015-z","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor (CAR) T cells have improved the cure rate and quality of life of patients with lymphoid malignancies but have yet to demonstrate clinical benefits in solid tumors. Thus, several CAR-engineering strategies are currently being explored to overcome the functional limitations and the high cost of CAR T cells. Key among these are CAR-engineered innate immune cells, such as natural killer (NK) cells, NK T (NKT) cells, γδ T cells and macrophages. In this Review, we discuss the potential and limitations of efforts to develop and use innate immune CAR-engineered cells for cancer immunotherapy.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":" ","pages":""},"PeriodicalIF":23.5000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The landscape of CAR-engineered innate immune cells for cancer immunotherapy.\",\"authors\":\"Ourania Tsahouridis, Max Xu, Feifei Song, Barbara Savoldo, Gianpietro Dotti\",\"doi\":\"10.1038/s43018-025-01015-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric antigen receptor (CAR) T cells have improved the cure rate and quality of life of patients with lymphoid malignancies but have yet to demonstrate clinical benefits in solid tumors. Thus, several CAR-engineering strategies are currently being explored to overcome the functional limitations and the high cost of CAR T cells. Key among these are CAR-engineered innate immune cells, such as natural killer (NK) cells, NK T (NKT) cells, γδ T cells and macrophages. In this Review, we discuss the potential and limitations of efforts to develop and use innate immune CAR-engineered cells for cancer immunotherapy.\",\"PeriodicalId\":18885,\"journal\":{\"name\":\"Nature cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":23.5000,\"publicationDate\":\"2025-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s43018-025-01015-z\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s43018-025-01015-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体（CAR） T细胞已经提高了淋巴细胞恶性肿瘤患者的治愈率和生活质量，但尚未证明在实体瘤中的临床疗效。因此，目前正在探索几种CAR- T工程策略，以克服CAR- T细胞的功能限制和高成本。其中的关键是car工程先天免疫细胞，如自然杀伤细胞（NK）、NKT细胞（NKT）、γδ T细胞和巨噬细胞。在这篇综述中，我们讨论了开发和使用先天免疫car工程细胞用于癌症免疫治疗的潜力和局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The landscape of CAR-engineered innate immune cells for cancer immunotherapy.

Chimeric antigen receptor (CAR) T cells have improved the cure rate and quality of life of patients with lymphoid malignancies but have yet to demonstrate clinical benefits in solid tumors. Thus, several CAR-engineering strategies are currently being explored to overcome the functional limitations and the high cost of CAR T cells. Key among these are CAR-engineered innate immune cells, such as natural killer (NK) cells, NK T (NKT) cells, γδ T cells and macrophages. In this Review, we discuss the potential and limitations of efforts to develop and use innate immune CAR-engineered cells for cancer immunotherapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.